Testing effectiveness (Phase 2)Study completedNCT03278665
What this trial is testing
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Who this might be right for
Malignant Melanoma
4SC AG 40